<DOC>
	<DOCNO>NCT01462136</DOCNO>
	<brief_summary>The purpose study assess relationship renal function pharmacokinetics ACHN-490 Injection .</brief_summary>
	<brief_title>PK Study ACHN-490 Injection Renally Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Male female subject 18 75 year age body mass index ≥ 19 ≤ 32 kg/m2 , weight ≥ 40 kg . 2 . Normal renal function ( Group I ) , preexist renal impairment ( Groups II IV ) . The disease process responsible underlying renal dysfunction must stable time study entry , subject episode acute renal disease year prior dose . 3 . Two CrCl determination obtain screen portion study , low value within 25 % high value . 4 . Females childbearing potential ( define less one year postmenopause ) eligible enrollment breast feeding , negative serum pregnancy test study entry , willing use highly effective method contraception* least three month study drug administration , study , least one month study completion . 5 . Subjects stable health judge investigator base laboratory criterion clinically significant finding medical history physical examination . 6 . Subjects willing comply study activity procedures provide write informed consent prior study procedure sign date HIPAA authorization form . 1 . Subjects require hemodialysis peritoneal dialysis 2 . Unstable cardiovascular disease , 3 . Uncontrolled hypertension , asthma , diabetes ( type I type II ) , thyroid disease , seizure disorder . 4 . Myasthenia gravis , neuromuscular disorder . 5 . Known infection Hepatitis B ( antigen positive ) , Hepatitis C ( antibody positive ) , HIV . 6 . Active malignancy ; carcinoma situ prostate skin ( basal cell squamous cell ) permit . 7 . Presence function transplant organ blood procedure . 8 . Significant change either overthecounter prescription medication supplement within two week prior dose , define new medication dosage adjustment significant judgment investigator medical monitor . 9 . Use drug know cause renal disease nonsteroidal antiinflammatory drug two week prior dose . 10 . History significant hearing loss family history hearing loss , exclude age relate ( ≥ age 65 ) hearing loss . A prior diagnosis sensorineural hearing loss Ménière 's disease . 11 . Clinically significant illness , include viral syndrome within three week dose . 12 . Current participation clinical study investigational product . 13 . Taken investigational medication/therapy within 30 day 5 halflives , whichever longer , dose ACHN490 Injection . 14 . Consumed 28 unit ethanol per week time 6 month dose ( 1 unit ethanol equivalent 8 ounce beer , 4 ounce wine , 1 ounce spirit ) history alcoholism and/or drug/chemical abuse . Also , consumption amount ethanol within 48 hour ACHN490 Injection dose . 15 . Donated 500 mL blood within 60 day prior sign inform consent form . 16 . Previous participation ACHN490 Injection study . 17 . Known hypersensitivity Aminoglycosides component ACHN490 Injection . 18 . Any medical , psychological , social condition , opinion principal investigator ( PI ) medical monitor , would prevent subject fully participate study , would represent concern study compliance would constitute safety concern subject . 19 . An employee investigator study center direct involvement propose study study direction Investigator study center , family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>PK study</keyword>
</DOC>